Vaccinex seems to be the topic of conversation over at Stockhouse.

Is it possible that Vaccinex has developed a way to cross the BBB with sufficient payload that they don't need xB3 to get them there which rendered the agreement they made with Bioasis in 2016 unuseful and unnecessary? 

http://www.marketwired.com/press-release/bioasis-enters-into-a-license-agreement-with-vaccinex-inc-2160184.htm

Koo